Uganda’s health-startup innovation, BreastIT – a portable diagnosis tool for breast abnormalities as cancer, was among the five (5) finalist innovations for the 2018 Pistoia Alliance President’s Startup Challenge. The team lead by Chief Executive and Co-Founder; Moris Atwine, Alvin Kabwama, and David Mwesigwa, will pitch their startup to the Pistoia Alliance membership in Boston on October 10, 2018 to have a chance of winning a cash prize of USD$20,000 (roughly about UGX76.8 million). Meanwhile, all the five finalists received USD$5,000.
On addition to the cash prize, the finalists will have a chance to meet industry leaders and investors during the conference in Boston while the final two winners will receive 6 months of mentorship and support from a leading industry expert from amongst our membership.
BreasIT is competing alongside four other startups; 1. Clarity Genomics – providing host-microbiome data analysis and interpretation services for clinical research, 2. Riffyn – developed experimental designs and data across R&D teams for real-time analytics, 3. uFraction8 – developing a solution designed to address the need for a scalable, low energy primary recovery solution for bioproducers using unicellular cultures, and 4. UniteLabs – developing easy-to-use, reusable and flexible automation that adapts to the ever-changing needs of life science research.
The challenge on call for applications, focused on startups that aim at impacting the way life science R&D is performed.
BreastIT is a portable diagnosis tool for breast abnormalities as cancer. It’s a handheld, pocket sized photo-acoustic imaging system that empowers radiologists to make focused assessments and accelerate treatment decisions at the point of care. Radiologists can be able to take decisive action, refer patients quickly, optimize the course of treatment reducing the overall cost of care in low resource settings.
As breast IT accelerates the rate of early breast cancer detection, its primary impact is increasing the survival rate of women who live with the condition. The portability of the device means that especially women in poor and rural areas are able to benefit from the technology.
The team has high ambitions, hoping to launch their product worldwide and then use the data collected to support academic research of breast cancer.
Early this year, the team also were selected finalist for the Vodafone’s F-Lane Accelerator.